News & Events

Investor Relations

Lipidor’s Phase III study of AKP02 for treatment of psoriasis now fully recruited, results expected Q3 2022

STOCKHOLM, Sweden, 11 July 2022 – Lipidor AB (publ) (Nasdaq… Read More

Investor Relations R

Bulletin from the annual general meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 2 June 2022 – The following resolutions were… Read More

News

Lipidor updates on Phase III study of AKP02 in treatment of psoriasis – half of patients now recruited

STOCKHOLM, Sweden, 20 May 2022 – Lipidor AB (publ) (Nasdaq… Read More

Events

Biotech Show Case Conference. San Francisco, USA

We will be present during the BIOTECH SHOWCASE conference… Read More

Events

CPHI Worldwide. Frankfurt, Germany

We will be present during CPhI Worldwide in Frankfurt,… Read More

Events

Japan

The Lipidor team will be in Japan, 21-25 October… Read More